Pipeline 2018-04-11T23:30:10+00:00

Product Pipeline

EyePoint has developed three FDA-approved products utilizing our proprietary DurasertTM Technology.

We are utilizing our Durasert bioerodible technology platform in collaboration with other pharmaceutical companies to develop new sustained-release products to treat retinal diseases and other ocular conditions.

We are expanding our focus beyond eye diseases to leverage our Durasert Technology for the treatment of musculoskeletal conditions.

Product/ProgramPhase
Dexycu (dexamethasone intraocular suspension) 9%Approved
Durasert three-year treatment
Potential Indication: posterior segment uveitis
Filing
Durasert shorter duration treatment
Potential Indication: posterior segment uveitis
Preclinical
Durasert TKI
Potential Indication: Wet AMD
Preclinical
Durasert
Potential Indication: Knee OA
Phase 1
Front of the eye diseasePreclinical
Back of the eye diseasePreclinical

Dexycu (dexamethasone injectable suspension) 9%

click here for full Prescribing Information

Please complete the form below to receive information on the availability of Dexycu.

DurasertTM Three-year for Posterior Uveitis

Potential Indication: posterior segment uveitis

EyePoint filed an NDA in January 2018 and received a target PDUFA date of November 5, 2018 from the FDA. EyePoint has out-licensed the rights for Europe, Middle East and Africa (EMEA) to Alimera Sciences as part of a broader amendment to its current licensing and collaboration agreement for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg.

DurasertTM Shorter Duration for Posterior Uveitis

Potential Indication: posterior segment uveitis

EyePoint is currently developing a shorter-duration sustained-release fluocinolone acetonide product in the proven DurasertTM Technology.

DurasertTM Bioerodible TKI

Potential Indication: Wet AMD

EyePoint is focused on developing a sustained-release bioerodible device containing a tyrosine kinase inhibitor (TKI) to assess its potential to treat wet AMD. In-vitro release profiles have been assessed for several TKIs. EyePoint is actively seeking partners interested in advancing the program to clinical-stage development.

DurasertTM for Knee Osteoarthritis (OA)

Potential Indication: Knee OA

EyePoint is working with the Hospital for Special Surgery (HSS) in New York City on a titanium screw drug implant containing the corticosteroid dexamethasone. The screw implant utilizes the DurasertTM Technology and is designed to release a low dose of dexamethasone. This investigator-initiated study is being conducted by HSS. A total of 6 patients have been enrolled as of the 2nd quarter of 2017 and will be followed for a period 6 months.